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Abstract
Elite suppressors or controllers (ES) are HIV-1 infected patients who maintain undetectable viral loads without
treatment. While HLA-B*57-positive ES are usually infected with virus that is unmutated at CTL epitopes, a single,
dominant variant containing CTL escape mutations is typically seen in plasma during chronic infection. We
describe an ES who developed seven distinct and rare escape variants at an HLA-B*57-restricted Gag epitope over
a five year period. Interestingly, he developed proliferative, de novo CTL responses that suppressed replication of
each of these variants. These responses, in combination with low viral fitness of each variant, may contribute to
sustained elite control in this ES.
Findings
Elite suppressors (ES) are HIV-1 infected individuals who
control viremia naturally, maintaining clinically undetect-
able levels of virus in the plasma (< 50 copies of HIV-1
RNA/ml) without antiretroviral therapy[1-3]. We have
previously shown that HIV-1 sequences amplified from
resting CD4
+T cells of these patients are distinct from
those amplified from free virus in the plasma, with CTL
escape mutations apparent in the plasma virus but largely
absent in proviral DNA [4-6]. We have also shown that
the escape mutations present in plasma virus generally do
not vary over time. This suggests that virus in ES achieves
a balance between fitness and CTL escape which elimi-
nates the development of further nonsynonymous muta-
tions during chronic infection, despite ongoing viral
replication [7-9].
The HLA-B*57 and B*5801 alleles are overrepresented
in ES and are thought to play a causative role in control
of viremia in these patients [1-3]. The TW10 epitope in
Gag (amino acids 240-249) is a well-characterized,
immunodominant epitope restricted by these alleles.
Escape via a T242N mutation frequently occurs early in
the majority of HLA-B*57 chronic progressors (CP) [10]
and ES [4,11-14]. Compensatory mutations upstream of
TW10 in the CypA binding site partially or completely
compensate for the negative fitness impact of the T242N
mutation [15]. Interestingly, some ES develop rare, alter-
native mutations in TW10 [4,13], some of which also
have dramatic fitness defects [13].
Here we describe an HLA-B*57-positive ES who dis-
played unprecedented sequence variation at the TW10
epitope while never acquiring the T242N mutation. Seven
different TW10 variants were observed in the plasma
sequences from this patient over five years, all of which
otherwise shared the same gag backbone. Only two of the
seven variants have been previously documented in the
LANL database, and together these two variants were only
present in 5 of the 1510 Clade B HIV-1 sequences in the
database http://www.hiv.lanl.gov/content/sequence/HIV/
COMPENDIUM/2010compendium.html. Using IFN-g
ELISPOT analysis, we previously showed that this patient,
ES8, was able to mount a CTL response against each of
the variants [6]. To understand the presence of this atypi-
cal ongoing evolution, we also determined the impact of
these mutations on viral replication capacity and multiple
aspects of the CTL response.
Autologous plasma variants from ES8 contain rare
mutations in TW10 and are significantly less fit than
proviral variants or laboratory isolates
Multiple HIV-1 clones were amplified from the plasma of
ES8 over the course of five years. To prevent resampling,
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limiting dilution “digital” nested PCR as previously
described [4,11]. Four clones obtained from one time
point were identical to the dominant proviral Gag and
contained no mutations in HLA-B*57 targeted epitopes.
The other 64 Gag clones, however, shared mutations dis-
tinguishing them from the dominant proviral variants.
These plasma Gag clones were identical to each other
with the exception of variation at the TW10 epitope. In
total, seven different variations in the TW10 epitope
were observed in the plasma Gag sequences (Figure 1).
These variants were quite rare in the LANL database,
and none of the variants possessed the typical T242N
mutation.
To determine the impact of the mutations on viral
replicative capacity (referred to as “fitness” herein), we
utilized site-directed mutagenesis to introduce the seven
observed plasma gag variants into the backbone of one
ES8 plasma gag clone. As all plasma clones were identi-
cal outside of the TW10 epitope, this backbone was
representative of all plasma clones. This backbone con-
tained the I147M substitution in the HLA-B*57
restricted IW9 epitope [4], but no escape mutations in
other HLA-B*57 restricted Gag epitopes. In addition to
mutating TW10 to express each of the seven plasma
variants, we mutated the epitope to express the T242N
mutation and to express wild type TW10 (TSTLQE-
QIGW). We then inserted these 9 gag variants into an
NL43 provial clone in which nef has been replaced by
GFP (NL43nGFP) to make infection detectable by flow
cytometric analysis. We compared the fitness of these
nine variants to three control variants: wild type NL43,
wild type NL43 with the T242N mutation, and wild type
NL43 with gag replaced by gag of the dominant proviral
variant of the patient (Figure 2a). The dominant proviral
v a r i a n to fE S 8h a dn om u t a t i o ni na n yH L A - B * 5 7
restricted epitope. Input virus was standardized by nor-
malizing to transfection efficiency, and fitness was
assessed as previously described [16].
As shown previously, the T242N mutation slightly
reduced fitness of otherwise wild type NL43nGFP
[15,17]. Viruses expressing the I147M mutation in the
IW9 epitope and any of the ES8 plasma mutations in
TW10, however, showed considerably less infection of
donor cells than the control viruses. Virus containing
the T242N mutation in the patient’sp l a s m agag back-
bone also showed little replication. Interestingly, rever-
sion of the TW10 mutations seen in the plasma variants
Date Source  Number 
of Clones
IW9 sequence TW10 sequence
04/05  Proviral     11
04/07  Proviral      7
10/09  Proviral     37
08/04  Plasma    15
04/05  Plasma     2
07/08  Plasma     5
11/08  Plasma     7
01/09  Plasma    12
08/09  Plasma    16
10/09  Plasma    11
Figure 1 Proviral and plasma virus variants from ES8 spanning five years. Clones were amplified using nested, limiting dilution PCR and
RT-PCR. Sequence logos were created utilizing the WebLogo program from University of California at Berkeley http://weblogo.berkeley.edu/. For
clones amplified at each time point, Logos show the proportion of an amino acid residue and substitutions at a given site. The date the
sequence was obtained, the source of the sequence, and the number of clones for each time point are shown, as well as the sequence of the
HLA-B*57-restricted IW9 and TW10 epitopes.
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Figure 2 Mutations present in the TW10 epitope of plasma viral variants dramatically impact viral fitness. (A) Schematic for the
development of NL43nGFP based viruses to test the impact of plasma TW10 variants on viral fitness. Gag from ES8-1a virus which contains the
TSTLAEQVAW TW10 mutant was mutated using site-directed mutagenesis to produce gag with the six other variants present in the plasma, as
well as wild type TW10 and T242N on this ES8-1a backbone. Site-directed mutagenesis was also utilized to insert T242N into the NL43 gag, and
gag from ES8-17 was amplified. Each of these gag mutants were then inserted into NL43eGFP backbone. All viruses derived from ES8-1a, the
viral variant representing plasma viral variants, also had the I147M mutation, as indicated. (B) Fitness of viral variants was measured on day 6 post
infection. Data shown are infection of two uninfected donors infected with two separate virus preparations in duplicate. Percent infection was
normalized to transfection efficiency, and to the percent infection of WT NL43 which was on average 42%. (C) Replication of viral variants ES8-17
and ES8-1a. ES8-17 is wild type at the TW10 epitope and was cultured from resting CD4
+ T cells from ES8. ES8-1a has mutation at TW10 and
was cultured from activated CD4
+ T cells. Results are the average of triplicate samples of p24 supernatant of activated CD4
+ T cells infected with
each virus. P-values shown above each time point compare the p24 of ES8-17 and ES8-1a using a one-tailed Student’s T-test.
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Page 3 of 7to a wild type TW10 motif (ES8WT) did not rescue
viral fitness and, if anything, decreased viral fitness
further. This may suggest that compensatory mutations
exist in the plasma variants which partially rescue fitness
defects caused by the TW10 mutations, but that these
compensatory mutations reduce the fitness of a virus
with wild type TW10. Virus with Gag derived from pro-
virus of ES8 (ES8WTProv) had an intermediate level of
fitness (Figure 2b). The proviral-derived Gag had no
mutations in either the IW9 or TW10 epitopes, suggest-
ing that mutations in the HLA-B*57 restricted epitopes
are not the only factors impacting the fitness of virus
from ES8.
To elucidate the relevance of the TW10 mutations in
virus obtained directly from the patient, we compared
the fitness of two viral variants which we cultured from
ES8. ES8-1A and ES8-17 are variants cultured from acti-
vated CD4
+T cells and resting CD4
+T cells from the
patient, respectively [18]. The ES8-1A variant expresses
mutant IW9 and TW10 epitopes, specifically the
TSTLAEQVAW variant, and is thus identical to some
plasma viral clones. The ES8-17 virus is unmutated at the
TW10 and IW9 epitopes. We infected activated CD4
+T
cells from uninfected donors with equal amounts of each
virus via spinoculation [19] in triplicate, as well as the
laboratory strain Ba-L (virus quantified using p24 assay),
and found that the ES8-17 variant showed similar repli-
cation kinetics to the laboratory strain, whereas ES8-1A
had reduced replication kinetics (Figure 2c). Together,
these studies examining the fitness of viral variants from
this patient show that plasma variants were less fit than
the ancestral virus which was retained in the proviral
compartment and less fit than wild type NL43. The low
fitness of the plasma variants relative to proviral suggests
that viral fitness is a consequence rather than a cause of
elite control in this patient.
The CD8
+T cell response to autologous plasma virus is
proliferative and de novo
To examine the CTL response to the patient’s autologous
variants, we selected the five TW10 variants which were
most highly represented in the plasma and evaluated the
ability of CD8
+T cells from ES8 to respond to these pep-
tides in comparison to WT TW10, or TW10 containing
the T242N mutation. Using IFN-g ELISPOT, we had pre-
viously shown that CTL from ES8 exhibited a strong,
high-avidity IFN-g response to all five variants while fail-
ing to respond to TW10 with the T242N mutation [6].
We considered the possibility that there would be differ-
ences in the kinetics of the IFN-g response to the autolo-
gous epitopes, however, and therefore measured the
response to autologous viral variants over a shorter time
period, from 2 hours, 4 hours, and 6 hours after exposure
to peptide (Figure 3a). We again found comparable IFN-g
responses to the wild type TW10 and the autologous var-
iants and no response to the T242N mutant.
While IFN-g provides a measure of whether an antigen
is recognized by CTL, IFN-g is not a good measure of an
effective CTL response and does not correlate with con-
trol of viral replication [20-22]. The capacity of CD8
+T
cells to proliferate in response to HIV-1 antigen, how-
ever, is associated with control of HIV-1 viremia [23,24].
CFSE analysis was therefore used to determine whether
CTL proliferated in response to the escape mutants. In
addition, we looked at CFSE in conjunction with IFN-g
and HLA-B*57 TW10 tetramer staining to elucidate the
population of CD8
+T cells responding to peptide. We
found that the vast majority of IFN-g producing cells
were also CFSElow, suggesting that cells producing cyto-
kines in response to peptides were also proliferating
(Figure 3b). Interestingly, we found that cells responding
to the patient’s autologous peptides did not react to the
tetramer, and only wild type TW10 elicited a response
from tetramer staining cells (Figure 3c). This implies that
the response to the patient’s autologous peptides was the
result of an entirely de novo response rather than cross-
reactivity by T cells specific for wild type TW10 peptides.
CTL from ES8 suppress viral replication
To explore the strength of the patient’s CTL response to
autologous and wild type TW10, we measured the ability
of CD8
+ T cells to suppress the replication competent
pseudo-type viruses described in Figure 2a. We stimulated
PBMC from ES8 with three autologous TW10 variants
(TSTLAEQVAW, TSTLTEQIAW, TSTLTEQVAW) as
well as wild type TW10 for 6 days, and then isolated CD8
+T cells from these PBMCs. We then infected PHA acti-
vated CD4
+T cells from ES8 with the replication compe-
tent viruses constructed to express these TW10 variants,
and co-cultured the infected cells with each CD8
+Tc e l l
population that had been stimulated with the four pep-
tides, or with unstimulated CD8
+T cells. As shown in
Figure 4a, CD8
+T cells that were not pre-incubated with
HIV peptides were as efficient as CD8+ T cells that had
been stimulated with peptides in inhibiting replication of
both wild type virus and escape mutants. This highlights
once again the remarkable ability of CTL from this ES to
suppress viral replication of both autologous and non-
autologous virus without exogenous stimulation.
While cross-reactivity between wild type and mutant
epitopes has been documented, de novo responses to
mutated HIV-1 epitopes are rare. With regard to HLA-
B*57-restricted epitopes, one study suggested that de
novo CTL responses to autologous epitope variants
emerged more frequently in children than in adults [25].
However, the emergence of de novo responses to mutant
TW10 variants has been observed by one group in both
CP and LTNPs[12]. We [4] and others [13] have reported
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Page 4 of 7de novo responses to escape mutants in ES, but these stu-
dies have looked only at IFN-g secretion. IFN-g is not the
ideal measure of an effective CTL response and does not
correlate with immune protection [20-22]. In contrast,
HIV-specific CD8
+ T cells that proliferate in response to
antigen have been associated with perforin secretion and
effective immune control of viral replication [24].
Furthermore the ability of primary CD8
+ T cells to inhi-
bit HIV replication has been shown to be a correlate of
immunity [26,27]. We show here that CD8
+ Tc e l l sf r o m
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Figure 3 CD8+ T cells from ES8 mount a proliferative response to autologous TW10 variants. (A) CD8
+ T cells from ES8 mount a strong
response to wild type TW10 and autologous variants, but not to TW10 with the T242N mutation. IFN-g ELISPOT measuring the response of CD8
+ T cells from ES8 to wild type TW10, autologous variants, and the T242N mutant. Data is from 2 hours (left), 4 hours (center), and 6 hours
(right) of stimulation with the peptides. (B) IFN-g
+ CD8
+ lymphocytes that have been stimulated with wild type TW10 and autologous variants
are undergoing proliferation. Representative dot plot and histogram shown for stimulation with one of the autologous mutants, TSTLTEQVAW
(top). Gating is on the population of CD8
+ T cells that are IFN-g
+ (bottom). (C) HLA-B*57 tetramer
+ cells are producing IFN-g only in response to
wild type TW10 peptide, but not to autologous variants. Representative dot plot and histogram shown for stimulation with one of the
autologous mutants, TSTLTEQVAW (top left) and wild type TW10 (top right). Gating is on CD8
+ T cells (bottom). Total of 500,000 events were
collected for panels B and C, and the peptide with which cells were stimulated indicated in the legend.
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Page 5 of 7this patient proliferate effectively and inhibit replication
of multiple autologous escape variants. This may explain
his continued elite control.
In this study we describe an ES whose immune system
has selected for seven rare TW10 variants in Gag. The
development of these variants was apparently due to the
selective pressure placed on the virus by the CTL response
to the wild type TW10 epitope, as shown in Figure 3c.
These mutants have dramatically reduced viral fitness and
are continuing to evolve over time. It is not clear why the
T242N mutation never developed in this patient, analysis
of TW10-specific T cell receptors in patients who develop
rare alternate mutations in this epitope may be revealing.
The continued evolution in this patient is striking as the
typical ES has one epitope variant present in the plasma
which remains constant [6], but the presence of multiple
variants may be partially due to the fact that this patient
has maintained higher viral loads (mean of 26 copies/ml)
than the other ES in our cohort [28]. ES8 has developed
de novo CTL responses to the variants which proliferate
in response to antigen and suppress viral replication.
Further studies will be needed to determine whether the
induction of de novo proliferative suppressive CTL
responses is feasible and protective.
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